A news story is being published about Rusan Pharma’s investment of Rs 300 crore in the new API facility in MP’s Pithampur. This news is circulating on the web and people are trying to collect each and every detail about the news. Pharmaceutical company Rusan Pharma launched a new active pharmaceutical ingredients facility. This launch took place on Saturday in Pithampur, Madhya Pradesh. This news is circulating on the web and attracting people’s attention. What happened? What’s the whole deal behind the launch? We will discuss everything in this article. We continue the article.
Rusan Pharma unveils Rs 300 crore API manufacturing plant
According to the report, this facility is set to manufacture 400 API metrics per year and is expected to generate more than 300 jobs. The organization has made an investment of Rs 300 crore in the facility, which is situated within the Pithampur Special Economic Zone. The new arrangement will champion Rusan Pharma’s existing API capability, motivating it to provide critical APIs to address the growing demand for its pain management and addiction treatment products in India and globally. We will tell you more important details about the news, which you will find in the next section of the article.
According to the report, the organization is famous for increasingly inventive products such as buprenorphine sublingual tablets and buprenorphine naloxone, which are used in the treatment of drug abuse, transdermal lidocaine, apomorphine injections and which is used for Parkinson’s treatment, buprenorphine. and indigenous formulations of fentanyl. Not only this, they also make transdermal nicotine patches for smoking cessation. Kunal Saxena, who holds the position of Managing Director of Rusan Pharma, said that with an investment of approximately Rs 300 crore in two phases, this new API facility will increase the size of its current API manufacturing capacity of 40 metric tonnes. at Ankleshwar to 400 metric tonnes at Pithampur. Scroll down the page to learn more about the news.
Furthermore, the company’s statement revealed that the current GMP permit for its supply of final API formulations has the capacity to meet 90 percent of the global demand. The company is approved by several authorities, including the South African Health Products Regulatory Authority, Health Canada, the European Union, the United Arab Emirates and the Australian Therapeutic Goods Administration. If we get more details, we will inform you first on the same site. Stay tuned to us for more updates.
Categories: Trending
Source: vtt.edu.vn